OKYO Pharma Execs to Present at H.C. Wainwright Ophthalmology Conference
Event summary
- OKYO Pharma executives to present at H.C. Wainwright's virtual ophthalmology conference on July 22, 2026.
- Presenters include CEO Robert J. Dempsey and CMO Flavio Mantelli MD, PhD.
- Company plans to initiate a global Phase 3 clinical trial for urcosimod in H2 2026.
- Trial will enroll approximately 111 patients with neuropathic corneal pain (NCP).
The big picture
OKYO Pharma's presentation comes amid growing interest in innovative therapies for ophthalmic conditions, particularly as the market seeks effective treatments for neuropathic corneal pain. The company's upcoming Phase 3 trial represents a critical milestone that could validate its clinical strategy and attract further investment.
What we're watching
- Clinical Trial Execution
- The pace at which OKYO Pharma enrolls patients for its Phase 3 trial will determine timelines for potential regulatory approval.
- Market Positioning
- Whether OKYO can differentiate urcosimod in the competitive landscape of NCP treatments.
- Investor Sentiment
- How conference presentations impact investor confidence ahead of trial results.
Related topics